EVIDENCE PROFILE / PUBLISHED
Ipamorelin
A synthetic ghrelin-receptor agonist and growth-hormone secretagogue studied in people mainly for postoperative gastrointestinal recovery, without demonstrated efficacy in the pivotal published trial.
Evidence at a glance
- Human
- LimitedOne randomized trial in surgical patients and a one-person detection study.
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the Canadian and U.S. sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“Changing growth-hormone concentration is a pharmacodynamic observation. It does not prove muscle gain, recovery, longevity, or clinical benefit.”
Ipamorelin is often described by the hormone signal it can trigger. A biomarker response is not the same as a health outcome, and the main published patient trial did not meet its efficacy endpoints.
Identity and established aliases
Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist developed as a growth-hormone secretagogue. Ipamorelin free base and ipamorelin acetate are distinct bulk drug substances; study reports do not always make the chemical form clear.
Why researchers study it
Researchers initially characterized ipamorelin for selective release of growth hormone in animal models. Later human work focused on ghrelin-receptor effects on gastrointestinal motility and recovery after bowel surgery, measuring tolerance of food and other markers of gastrointestinal function.
Approved medicines and investigational uses
No ipamorelin active-ingredient record was returned by Health Canada's Drug Product Database under the reviewed name. FDA's 2024 review did not identify an approved ipamorelin drug and proposed against adding the free base and acetate to the relevant U.S. compounding list. These are jurisdiction-specific findings.
The principal published human investigation evaluated intravenous ipamorelin for postoperative ileus after bowel resection. A trial registration documents the research plan and completion; the peer-reviewed paper supplies the outcome evidence.
What human studies show
The multicentre randomized phase 2 study enrolled 117 surgical patients and compared intravenous ipamorelin with placebo. It found no statistically significant difference in the key time-to-tolerated-meal endpoint or secondary efficacy analyses.
The publication described overall adverse-event rates as similar, but FDA's fuller review noted deaths and higher rates of hypokalemia and hyperglycemia in treated participants; causality for the deaths was unclear. FDA also found no clinical safety data for subcutaneous administration. Evidence from one volunteer in an anti-doping metabolism study adds detection information, not clinical benefit or adequate safety evidence.
What cells and animal studies show
Early pharmacology in rats and swine found growth-hormone release with less effect on some other pituitary hormones than comparator secretagogues. That selectivity label comes from preclinical experiments and does not establish a favourable long-term endocrine profile in people.
Popular claims and evidence limits
Popular claims include muscle gain, fat loss, recovery, improved sleep, and anti-aging effects. The reviewed human studies did not test or establish these outcomes. A substance's ability to trigger growth-hormone release cannot be used as a shortcut to those claims.
What remains uncertain
Unresolved questions include chemical form, route-specific absorption and safety, long-term hormonal and metabolic effects, glucose intolerance, fluid retention, immunogenicity, peptide impurities, and whether any clinical use has a favourable benefit-risk balance. The negative postoperative-ileus result does not answer other claims; it shows why each outcome must be tested directly.
